Elevation Wealth Partners
NBIX icon

Elevation Wealth Partners’s Neurocrine Biosciences NBIX Stock Holding History

Elevation Wealth Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.99K Hold
14
– – ﹤0.01% 1239
2026
Q2 		$2.36K Buy
+14
New +$2.08K ﹤0.01% 1175

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Seizert Capital Partners
Seizert Capital Partners Birmingham, Michigan $2.3B AUM 16.06% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Virginia Retirement Systems
Virginia Retirement Systems Richmond, Virginia $16.3B AUM 35.33% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
PKO BP Bankowy Universal Pension Society
PKO BP Bankowy Universal Pension Society Warsaw, Poland $340M AUM 228.33% 1-Year Est. Return
Fideuram Asset Management (Ireland)
Fideuram Asset Management (Ireland) Dublin 1 $4.57B AUM 30.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Elevation Wealth Partners's NBIX Position: Q3 2026 in Review

Elevation Wealth Partners held its Neurocrine Biosciences (NBIX) position steady in Q3 2026 at 14 shares worth $1.99K. The position accounts for ﹤0.01% of the portfolio, ranked #1239.

Elevation Wealth Partners first reported a position in NBIX in Q2 2026 and has held it in 2 quarters since. The position peaked at $2.36K in Q2 2026. 238 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Elevation Wealth Partners held 14 shares of Neurocrine Biosciences worth $1.99K as of Q3 2026.
  • Elevation Wealth Partners left its Neurocrine Biosciences share count unchanged in Q3 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q3 2026, its #1239 holding.
  • Elevation Wealth Partners first reported a position in Neurocrine Biosciences in Q2 2026 and has held it in 2 quarters since.
  • Elevation Wealth Partners's Neurocrine Biosciences position peaked at $2.36K in Q2 2026.
  • 238 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Elevation Wealth Partners's 13F filing for Q3 2026, filed 7 Oct 2026.